Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 December;50(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 December;50(4):330-3

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 December;50(4):330-3

Copyright © 2006 EDIZIONI MINERVA MEDICA

language: English

Platelet function after single [153Sm]EDTMP therapy in prostate cancer

Weiss K. 1, Palumbo B. 2, Palumbo I. 2, Palumbo R. 2, Granegger S. 3, Hiltunen J. 4, Sinzinger H. 3

1 Department of Nuclear Medicine Hospital Wr. Neustadt, Austria 2 Institute of Nuclear Medicine University of Perugia, Perugia, Italy 3 Department of Nuclear Medicine University of Vienna, Vienna, Austria 4 Laboratory of Radiochemistry, Department of Chemistry University of Helsinki, Helsinki, Finland


PDF


Aim. Aim of the study was to assess whetheré [153Sm] EDTMP therapy at a low-dose is associated with platelet activation.
Methods. In 29 patients suffering from metastatic prostate cancer platelet count and various platelet function parameters have been monitored for 2 months after a single (the first) application of 1.1 GBq mCi [153Sm]EDTMP.
Results. After 3 days insignificant signs of platelet activation (increase in malondialdehyde, adenosine diphosphate-induced platelet aggregation, decreased platelet sensitivity) occur, normalizing rapidly. At the nadir of platelet count (3-4 weeks) platelet aggregation response in non-count adjusted samples is somewhat lower, while activity per cell (count adjusted samples) is unchanged. Platelet proteins do not change at all. Insignificant activation of platelet function at day 3 is interpreted as an indicator of mild oxidation injury, late aggregation response changes in non-adjusted samples seem only to reflect temporarily decreased number of circulating platelets. Samarium-153-EDTMP therapy at doses (1.1 GBq) used in the Vienna-protocol is not associated with a significantly altered functional behavior of platelets.
Conclusion. We conclude that a single dose of 1.1 GBq 153Sm-EDTMP does not significantly affect in vivo and ex vivo platelet function.

top of page